Flamel Technologies Has Returned 21.4% Since SmarTrend Recommendation (FLML)
Comtex SmarTrend(R) - Wed Dec 24, 11:03AM CST
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on November 25th, 2014 at $14.23. In approximately 4 weeks, Flamel Technologies has returned 21.36% as of today's recent price of $17.27.
FLML: 17.01 (-0.98)
Nasdaq stocks posting largest percentage increases
AP - Fri Dec 19, 12:25PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
IMDZ: 34.96 (+0.78), FLML: 17.01 (-0.98), PETX: 17.05 (+0.42), GTWN: 18.00 (+1.70)
Flamel progresses on single dose narcolepsy treatment
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:13PM CST
FLML: 17.01 (-0.98), JAZZ: 165.33 (+1.83)
Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump(R) Sodium Oxybate
Marketwired - Fri Dec 19, 7:00AM CST
Flamel Technologies (NASDAQ: FLML) today announced that its second clinical study in healthy volunteers using its proprietary Micropump(R) technology applied to sodium oxybate has achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, confirming the results of a previous, first-in-man, study. The current dosing regimen for the standard of care, Xyrem(R) (sodium oxybate), in the United States is two equal, divided doses: the first dose at bedtime and the second dose 2.5 to 4 hours later. The elimination of the second dose for narcolepsy patients would not only provide more convenience, but may improve the benefit sodium oxybate provides as there will be no disruption to nighttime sleep. The potential for additional benefits, including improved safety, will be studied.
FLML: 17.01 (-0.98)
Shares of FLML Up 16.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 17, 9:53AM CST
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on November 25th, 2014 at $14.23. In approximately 3 weeks, Flamel Technologies has returned 15.95% as of today's recent price of $16.50.
FLML: 17.01 (-0.98)
Flamel Technologies Transfers Intangible Property to Irish-Based Subsidiary in Global Reorganization
Marketwired - Tue Dec 16, 7:30AM CST
Flamel Technologies (NASDAQ: FLML) announced today that it is moving all intangible property from its French entity to its Irish-based entity as a part of a global reorganization. The intangible property includes patents on its drug delivery platform technologies, clinical data sets and other intangible assets related to its pipeline of proprietary products in development. Flamel's proprietary drug delivery platforms include its Micropump(R) (and its applications to the development of liquid formulations LiquiTime(R) and of abuse-deterrent formulations Trigger Lock(TM)) and Medusa(TM) platforms. We anticipate the transfer will result in a one-time tax payment of approximately $14 million to the French government.
FLML: 17.01 (-0.98)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Flamel Technologies to Be Included in NASDAQ Biotech Index
Marketwired - Mon Dec 15, 7:25AM CST
Flamel Technologies (NASDAQ: FLML) announced today that its common stock has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective before market open on Monday, December 22, 2014. The NASDAQ Biotechnology Index was established in 1993, and is designed to track the performance of a set of securities listed on The NASDAQ Stock Market(R) (NASDAQ(R)) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is a modified market capitalization weighted index.
FLML: 17.01 (-0.98)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Why Flamel Technologies (FLML) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:39AM CST
Positive earnings estimate revisions suggest that analysts are becoming more optimistic on Flamel Technologies’ earnings for the coming quarter and year.
FLML: 17.01 (-0.98)
Flamel clears resistance
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:51PM CST
FLML: 17.01 (-0.98)
Flamel Technologies (FLML) in Focus: Stock Rises 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 7:37AM CST
Flamel Technologies SA (FLML) was a big mover last session, as the company saw its shares rise more than 8% on the day.
LCI: 42.29 (+1.79), FLML: 17.01 (-0.98), SCMP: 13.75 (+0.44), IG: 9.11 (-0.01)
Flamel Technologies Closes Sale of Development and Manufacturing Facility in Pessac, France to Recipharm AB
Marketwired - Mon Dec 01, 3:15PM CST
Flamel Technologies (NASDAQ: FLML) announced today that it has closed the sale of its development and manufacturing facility located in Pessac, France, to Recipharm AB that was announced on November 28, 2014. Under the agreement, Recipharm paid Flamel EUR 10.6 million and made an investment of EUR 10.5 million in Flamel's stock at a purchase price equal to the trailing 20-day average price.
FLML: 17.01 (-0.98)
Flamel Technologies plans divestiture of the Pessac facility
M2 - Mon Dec 01, 7:37AM CST
Flamel Technologies (NASDAQ:FLML) reported on Friday an agreement to sell its development and manufacturing facility located in Pessac, France for a purchase price of EUR10.6m before year end 2014.
FLML: 17.01 (-0.98)
3 Biotech Stocks With Jaw-Dropping Growth Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Nov 29, 1:01PM CST
The biotech industry has been absolutely soaring over the past two years, fueled by a rise in drug approvals, an merger-and-acquisition frenzy, and widespread reorganizations that have helped to mitigate the impact of the so-called "patent cliff."...
JNJ: 104.59 (+0.31), FLML: 17.01 (-0.98), GERN: 3.06 (+0.05), ICPT: 151.49 (+5.85), IBB: 299.80 (+5.12)
Flamel sells development & manufacturing facility to Swedish firm
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:49AM CST
FLML: 17.01 (-0.98), GSK: 42.85 (+0.11)
Flamel Technologies Sells Development and Manufacturing Facility in Pessac, France to Recipharm AB
Marketwired - Fri Nov 28, 7:15AM CST
Flamel Technologies (NASDAQ: FLML) announced today that it has entered into an agreement to divest its development and manufacturing facility located in Pessac, France, to Recipharm AB. Under the agreement, Recipharm will pay Flamel EUR 10.6 million and make an investment of EUR 10.5 million in Flamel's stock upon the closing of deal at a purchase price equal to the trailing 20-day average price. This new partnership allows Flamel to retain access to the development and manufacturing capabilities of Pessac and gain the use of any of Recipharm's other facilities for the development or manufacture of their proprietary pipeline if needed. The Pessac facility is not currently used for the production of Flamel finished products and Flamel intends to continue to outsource to third party contract manufacturing companies like Recipharm.
FLML: 17.01 (-0.98)
Recipharm acquires Flamel Technologies facility in Pessac, France
M2 - Fri Nov 28, 4:36AM CST
Recipharm AB (STO: RECI), a CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry, announced on Thursday the signing of an agreement with Flamel Technologies SA (Nasdaq:FLML), a drug delivery company, under which Recipharm will purchase Flamel's development and manufacturing facility located in Pessac, France.
FLML: 17.01 (-0.98)
Flamel Technologies: A Turnaround Story With Lots Of Upside
Small Pharma Analyst - at Seeking Alpha - Fri Nov 21, 12:05PM CST
FLML: 17.01 (-0.98), CNCE: 11.76 (+0.11)